Continued improvement in service margins and 14% growth in its installed base helped radiation oncology firm Accuray advance revenues in its third quarter of fiscal year 2012 (end-March 31).
Accuray reported total revenue of $101.8 million, compared with $54.7 million in the third quarter of fiscal 2011. The company also reported a net loss of $16.5 million in the third quarter, compared with a net loss of $1.2 million in the same quarter a year ago.
For the nine-month period, total revenue increased to $308.7 million, compared with $147.1 million in the same period of fiscal 2011. The company's net loss increased to $56.8 million during the period, compared with a net loss of $1.7 million in the nine-month period of last fiscal year.
Fiscal 2012 financial data reflect Accuray's consolidated results, including the results for TomoTherapy, which was acquired in June 2011, the firm said.
